Effects of talactoferrin alpha on lung adenoma prevention in A/J mice june 2, 2016

Donna E. Seabloom, Art R. Galbraith, Anna M. Haynes, Alisha S. Fujita, Jenny D. Antonides, Beverly R. Wuertz, Vernon E. Steele, Frank G. Ondrey, Lee W. Wattenberg

Research output: Contribution to journalArticle


Talactoferrin alpha is a promising non-toxic solid tumor cancer agent that met with success in the treatment of early-stage lung cancer clinically in humans. It is well-tolerated, anddendritic cell-stimulation is a target. We tested the efficacy of this agent in a chemoprevention setting in A/J mice. All groups received benzo[a]pyrene (B[a]P) by oral gavage in three doses of 3 mg/kg body weight over the course of one week. Animals were then randomized into 5 groups of 24 mice per group based on weight. Experimental diets oftalactoferrin alpha (Agennix Inc., Indianapolis, IN), at 1.40% and 0.42% of the diet, were started one week or eight weeks after the last dose of B[a]P. Animals were continued on the feeding schedule, weighed weekly, and monitored for toxicity. The study was concluded 16 weeks after administration of B[a]P. The agent was well-tolerated for the duration of the experiment and there was no observable toxicity or weight change. The average number of adenomas per animal was 14.04 ± 0.93 (N=24) in the control group, 18.14 ± 1.45 (N=22) in the early low-dose group, 16.70 ± 1.30 (N=23) in the late low-dose group, 15.09 ± 1.41 (N=23) in the early high-dose group and 14.46 ± 1.21 (N=24) in the late high-dose group. We conclude talactoferrinalpha is well-tolerated. However, it did not inhibit carcinogenesis at a dose of 1.4% or 0.42% of the diet, which equates to human doses of 1.12 g/kg/day or 0.336 g/kg/day.

Original languageEnglish (US)
Article numberAJTR0033800
Pages (from-to)875-880
Number of pages6
JournalAmerican Journal of Translational Research
Issue number3
StatePublished - 2018


  • A/J mice
  • Chemoprevention
  • Lung carcinogenesis
  • Talactoferrin alpha

Fingerprint Dive into the research topics of 'Effects of talactoferrin alpha on lung adenoma prevention in A/J mice june 2, 2016'. Together they form a unique fingerprint.

  • Cite this

    Seabloom, D. E., Galbraith, A. R., Haynes, A. M., Fujita, A. S., Antonides, J. D., Wuertz, B. R., Steele, V. E., Ondrey, F. G., & Wattenberg, L. W. (2018). Effects of talactoferrin alpha on lung adenoma prevention in A/J mice june 2, 2016. American Journal of Translational Research, 10(3), 875-880. [AJTR0033800].